ANI Pharmaceuticals (ANIP) announced that its Chairman, Patrick Walsh, will retire from the Company’s Board of Directors after a distinguished tenure of service. His retirement will be effective after completing his current term through the Company’s 2026 Annual Meeting of Stockholders. In addition, Mr. Walsh has stepped down from his position as Chairman. The Board of Directors has unanimously elected Thomas Haughey, a member of the Board since May 2018, as the next Chairman of the Board. As Mr. Haughey steps into his role as ANI’s Chairman of the Board, he will step down as Chair of the Audit and Finance Committee. Jeanne Thoma, a member of the Board since August 2020, and current Member of the Audit and Finance Committee and Member of the Compensation Committee, will assume the role of Chair of the Audit and Finance Committee. Mr. Haughey will continue to serve as a member of the Audit and Finance Committee and as a member of the Nominating and Corporate Governance Committee.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Highlights November 2025 Financial Strategies
- ANI Pharmaceuticals price target raised to $115 from $114 at Guggenheim
- ANI Pharmaceuticals’ Earnings Call Highlights Record Growth
- ANI Pharmaceuticals Reports Record Q3 2025 Results
- ANI Pharmaceuticals: Strong Commercial Execution and Promising Growth Prospects Reinforce Buy Rating